Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 2:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 77 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Cephalon, Inc. Clear all
Terminated Phase 2 Interventional

Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)

NCT00293111
View directory record Official record
Conditions
Multiple Myeloma
Interventions
SDX-101 (R-Etodolac)
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
8
States / cities
Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 7, 2026, 2:25 PM EDT
Completed Phase 2 Interventional Results available

Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome

NCT00621023
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Decitabine, Arsenic Trioxide and Ascorbic Acid
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 7, 2026, 2:25 PM EDT
Completed Phase 2 Interventional

Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD

NCT00315276
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, ADHD
Interventions
Modafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
18
States / cities
Little Rock, Arkansas • Lafayette, California • Northridge, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2012 · Synced Oct 7, 2026, 2:25 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT01305408
View directory record Official record
Conditions
Depression
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • Sherman Oaks, California • Temecula, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 7, 2026, 2:25 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)

NCT00682981
View directory record Official record
Conditions
Extensive-stage Small Cell Lung Cancer
Interventions
Obatoclax, Carboplatin/etoposide
Drug
Lead sponsor
Gemin X
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
32
States / cities
Huntsville, Alabama • Muscle Shoals, Alabama • Scottsdale, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Oct 7, 2026, 2:25 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Armodafinil for Fatigue Associated With Taxanes Alone or in Combination With Other Agents

NCT00825227
View directory record Official record
Conditions
Fatigue, Chemotherapy Side Effects
Interventions
Armodafinil 150 mg/day, Placebo,
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
29
States / cities
Muscle Shoals, Alabama • Burbank, California • Fountain Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 7, 2026, 2:25 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy

NCT00107796
View directory record Official record
Conditions
Narcolepsy
Interventions
Modafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
6 Years to 16 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2012 · Synced Oct 7, 2026, 2:25 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance

NCT00711516
View directory record Official record
Conditions
Excessive Sleepiness
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Burlingame, California • San Diego, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 7, 2026, 2:25 PM EDT
Completed Phase 3 Interventional Results available

Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain

NCT00813488
View directory record Official record
Conditions
Chronic Pain
Interventions
Fentanyl Buccal Tablet, Immediate release oxycodone
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
50
States / cities
Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 7, 2026, 2:25 PM EDT
Terminated Phase 1 Interventional

Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis

NCT01014546
View directory record Official record
Conditions
Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis
Interventions
Arsenic Trioxide, Ascorbic Acid, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Dietary Supplement · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
19 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 7, 2026, 2:25 PM EDT
Completed Phase 3 Interventional

A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder

NCT00236067
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Gabitril
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 64 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
21
States / cities
Birmingham, Alabama • Beverly Hills, California • Northridge, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 7, 2026, 2:25 PM EDT
Terminated Phase 3 Interventional Results available

Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT01121536
View directory record Official record
Conditions
Depression
Interventions
Armodafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
867 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
66
States / cities
Birmingham, Alabama • Anaheim, California • Cerritos, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 7, 2026, 2:25 PM EDT
Completed Phase 3 Interventional

Study to Evaluate the Efficacy of Modafinil Treatment in Patients With Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responders to Modafinil Treatment

NCT00343811
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Modafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
6 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
23
States / cities
Little Rock, Arkansas • Irvine, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 7, 2026, 2:25 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome

NCT00107809
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
Modafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
6 Years to 16 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
60
States / cities
Birmingham, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 7, 2026, 2:25 PM EDT
Completed Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain

NCT00214942
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
ORAVESCENT Fentanyl Citrate
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
17
States / cities
Jonesboro, Arkansas • Bakersfield, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 7, 2026, 2:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users

NCT01596673
View directory record Official record
Conditions
Drug Abuse
Interventions
45-mg hydrocodone bitartrate extended-release tablet (crushed or intact), Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Oct 7, 2026, 2:25 PM EDT
Completed Phase 2 Interventional

Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

NCT00236093
View directory record Official record
Conditions
Pain, Cancer, Sickle Cell Anemia, Severe Burns
Interventions
ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])
Drug
Lead sponsor
Cephalon
Industry
Eligibility
3 Years to 15 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
26
States / cities
Little Rock, Arkansas • Orange, California • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 7, 2026, 2:25 PM EDT
Completed Phase 2 Interventional

SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)

NCT00076349
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
bendamustine and rituximab
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
25
States / cities
Anchorage, Alaska • Concord, California • La Verne, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 7, 2026, 2:25 PM EDT
Completed Phase 3 Interventional Results available

Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness

NCT00228553
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, Chronic Shift Work Sleep Disorder
Interventions
Armodafinil 100 to 250 mg/day
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 64 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 7, 2026, 2:25 PM EDT
Completed Phase 3 Interventional

Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder

NCT00233675
View directory record Official record
Conditions
General Anxiety Disorder
Interventions
GABITRIL (tiagabine hydrochloride; CEP-6671)
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
28
States / cities
Mesa, Arizona • Beverly Hills, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 7, 2026, 2:25 PM EDT
Terminated Phase 3 Interventional Results available

A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Participants With Systemic Lupus Erythematosus

NCT01240694
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
CEP-33457
Drug
Lead sponsor
Cephalon, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
39
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2022 · Synced Oct 7, 2026, 2:25 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

NCT00893789
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Armodafinil, Placebo
Drug · Other
Lead sponsor
Cephalon, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
68
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 7, 2026, 2:25 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder

NCT00758498
View directory record Official record
Conditions
Excessive Sleepiness
Interventions
armodafinil, placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
427 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Atlanta, Georgia • Crestview, Kentucky • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 7, 2026, 2:25 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

NCT01073163
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Interventions
Bendamustine, Rituximab
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
36
States / cities
Tucson, Arizona • Little Rock, Arkansas • Fullerton, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Oct 7, 2026, 2:25 PM EDT